ABBOTT LABORATORIES
ABT evidence brief
What we can confirm
- BioSniper Score:
- 9.1 / 10
- Market Cap:
- $184.51B
- Lead Asset:
- 'tdxflx analyzer
What it means
What to watch
Prepared research question
What matters most for ABT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABT
ABBOTT LABORATORIES is a diversified healthcare company with a strong diagnostics pipeline and substantial financial resources, reporting $6.8B in cash and $52.1B in shareholders' equity as of March 31, 2026.
Key risk: High debt level
BioSniper Score
Based on 5 of 6 signals
Market Cap
$184.51B
Cash Runway
—
Lead Asset
'tdxflx analyzer
Next Catalyst
—
Financial data as of Mar 31, 2026.
Tracking 559 pipeline candidates · 24 clinical trials for ABBOTT LABORATORIES.
ABBOTT LABORATORIES is a diversified healthcare company with a strong diagnostics pipeline and substantial financial resources, reporting $6.8B in cash and $52.1B in shareholders' equity as of March 31, 2026.
- Cash & equivalents of $6,803.0M as of 2026-03-31 [sec]
- Total revenue of $11,164.0M as of 2026-03-31 [sec]
- Net income of $1,077.0M as of 2026-03-31 [sec]
- Shareholders' equity of $52,061.0M as of 2026-03-31 [sec]
- Total debt of $34,047.0M as of 2026-03-31 [sec]
What works
- Large cash position of $6.8B provides financial flexibility for R&D and acquisitions [sec]
- Extensive pipeline of diagnostic assays (e.g., axsym phenobarbital, cybrex phenytoin) supports revenue diversification [pipeline]
What to weigh
- Total debt of $34.0B is substantial relative to shareholders' equity of $52.1B [sec]
- Many pipeline candidates are older-generation assays (e.g., axsym, cybrex) which may face competitive pressure [pipeline]
Catalyst timeline
- 2023-10-11 · PDUFA: ARCHITECT AFP, Alinity i AFP — FDA decision on two diagnostic assays for alpha-fetoprotein; approval could expand Abbott's oncology testing menu.
- 2024-02-28 · Phase3_Start: Randomized Multicentre Open-label Study to Investigate the Non-inferiority of Itopride Hydrochloride 150mg Once Daily Versus Itopride Hydrochloride 50 mg Thrice Daily in Subjects With Functional (Non-ulcer) Dyspepsia or Chronic Gastritis — Initiation of a Phase 3 trial for itopride hydrochloride; results may support a new dosing regimen for gastrointestinal disorders.
Risks & what to watch (2)›
Key risks
- High debt level — Total debt of $34,047.0M as of 2026-03-31 could constrain future borrowing capacity [sec]
- Aging diagnostic pipeline — Many pipeline candidates are legacy platforms (axsym, cybrex) with limited growth potential [pipeline]
What to watch
- PDUFA date for ARCHITECT AFP and Alinity i AFP on 2023-10-11 [catalyst]
- Phase 3 start for itopride hydrochloride study on 2024-02-28 [catalyst]
Sources: Catalysts · Pipeline · Generated October 10, 2026 · How we verify sources →
Run ABBOTT LABORATORIES through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ABBOTT LABORATORIES facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 1.12 · 0% dilution
Lead: Approved
559 candidates
No upcoming catalysts tracked
3 buys · 3 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 1.5%
- Days to cover
- 1.8
- Shares short
- 22,536,486
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ABT short interestGovernance
Frequently asked questions
What is the AI investment thesis for ABBOTT LABORATORIES?
ABBOTT LABORATORIES is a diversified healthcare company with a strong diagnostics pipeline and substantial financial resources, reporting $6.8B in cash and $52.1B in shareholders' equity as of March 31, 2026.
Who is the CEO of ABBOTT LABORATORIES?
Mr. Robert B. Ford is the chief executive officer of ABBOTT LABORATORIES (ABT).
Where is ABBOTT LABORATORIES headquartered?
ABBOTT LABORATORIES (ABT) is headquartered in Abbott Park, IL, United States.
What therapeutic areas does ABBOTT LABORATORIES focus on?
ABBOTT LABORATORIES develops therapies across Oncology, Neurology, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.